BriaCell Therapeutics Corp.(BCTXW)Earnings, Financials & Key Ratios
BCTXW•NASDAQ
$0.00
Price updated Jun 20, 2026
AboutBriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$27M+16.6%
- Net Income-$26M-461.6%
- EPS (Diluted)-62.60-45.6%
- ROE-375.65%
BCTXW Price & Volume
BriaCell Therapeutics Corp. (BCTXW) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Capital Runway
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
Key Thesis Takeaways
- BriaCell Therapeutics remains in a high-risk pre-revenue stage, with its valuation and financial health heavily dependent on the successful execution of pivotal Phase 3 clinical trials.
- The company's reliance on dilutive equity financing to offset persistent operating losses, which reached $8.0M in 2025Q4, creates significant uncertainty regarding long-term shareholder value.
- Investors should monitor the company's ability to secure strategic partnerships, as the current cash position of $10.5M may be insufficient to sustain the high R&D burn rate required for its immunotherapy platform.
Verdict Logic
the company's reliance on dilutive financing to support a $8.0M quarterly net loss and the absence of commercial revenue streams present substantial risks to capital preservation.
BCTXW Growth Metrics
BriaCell Therapeutics Corp. (BCTXW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-447.8%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-140820.85%
Return on Capital
10 Years-119.17%
5 Years-148.51%
3 Years-228.68%
Last Year-340.57%
Peers Comparison
Key metrics vs top competitors for BriaCell Therapeutics Corp. (BCTXW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.00 | $976 | — | — | — | -375.65% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $1.02 | $129.73M | -0.91 | 14.85% | -173.02% | — | — | |
| $35.26 | $2.35B | -9.04 | -78.63% | -34596.22% | -50.72% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — |
Compare BCTXW vs Peers
BriaCell Therapeutics Corp. (BCTXW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when BCTXW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BCTXW Frequently Asked Questions
BriaCell Therapeutics Corp. (BCTXW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BCTXW profitable?
BriaCell Therapeutics Corp. (BCTXW) reported a net loss of $26.2M for fiscal year 2025.
Dividend & Returns
What is BCTXW's return on equity?
BriaCell Therapeutics Corp. (BCTXW) has a return on equity (ROE) of -375.6%. Negative ROE indicates the company is unprofitable.
What is BriaCell Therapeutics Corp.'s free cash flow?
BriaCell Therapeutics Corp. (BCTXW) had negative free cash flow of $28.2M in fiscal year 2025, likely due to heavy capital investments.